Accolade Stockholders Approve Merger with Transcarent

Story Highlights
Accolade Stockholders Approve Merger with Transcarent

Accolade ( (ACCD) ) has shared an announcement.

On March 27, 2025, Accolade, Inc. held a special meeting where stockholders approved the merger with Transcarent, Inc. The merger, initially agreed upon on January 8, 2025, will result in Accolade becoming a privately held company, with its shares no longer listed on public markets. The transaction is expected to be completed in the second quarter of 2025, pending customary closing conditions and regulatory approvals. This merger is significant for Accolade’s operations and market positioning, as it aligns with Transcarent’s focus on providing accessible and affordable healthcare solutions.

More about Accolade

Accolade, Inc. is a Personalized Healthcare company that provides healthcare experiences through virtual primary care, mental health services, expert medical opinions, and care navigation. Their solutions are designed to improve health outcomes and cost savings by addressing barriers to access and continuity of care. Accolade’s offerings are highly rated by consumers, consistently achieving satisfaction ratings over 90%.

YTD Price Performance: 104.39%

Average Trading Volume: 2,114,787

Technical Sentiment Signal: Hold

Current Market Cap: $573.1M

For a thorough assessment of ACCD stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App